Latest news with #ArcutisBiotherapeutics
Business Insider
08-07-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Arcutis Biotherapeutics (ARQT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Insulet (PODD) Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet yesterday and set a price target of $335.00. The company's shares closed last Monday at $300.70. According to Steed is a 4-star analyst with an average return of 7.0% and a 63.3% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Inspire Medical Systems, and Zimmer Biomet Holdings. Insulet has an analyst consensus of Strong Buy, with a price target consensus of $337.56, implying a 12.6% upside from current levels. In a report issued on June 23, TD Cowen also maintained a Buy rating on the stock with a $379.00 price target. Arcutis Biotherapeutics (ARQT) Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $21.00. The company's shares closed last Monday at $13.39. According to Ear is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 35.8% success rate. Ear covers the Healthcare sector, focusing on stocks such as Cartesian Therapeutics, ACADIA Pharmaceuticals, and Tectonic Therapeutic. Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $21.29, a 54.8% upside from current levels. In a report issued on July 2, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $20.00 price target.
Globe and Mail
23-06-2025
- Health
- Globe and Mail
Alopecia Areata Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight
"Alopecia Areata Drugs Market" Alopecia Areata companies are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, and others. (Albany, USA) DelveInsight's " Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The market report on Alopecia Areata presents up-to-date information on treatment approaches, emerging medications, the market share of different therapies, and the current as well as projected Alopecia Areata market size from 2020 to 2034, across seven major markets. The report includes details on the prevailing treatment practices and guidelines for Alopecia Areata, along with an analysis of market drivers, barriers, and unmet medical needs. This comprehensive assessment aims to identify the most promising opportunities and evaluate the overall potential of the Alopecia Areata market. Some facts of the Alopecia Areata Market Report are: According to DelveInsight, Alopecia Areata Market is expected to grow at a CAGR of ~27% by 2034. According to DelveInsight's patient-based forecasting model, the total market size of Alopecia Areata in the 7MM was around USD 180 million in 2023. Leading Alopecia Areata companies working in the market are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others Key Alopecia Areata Therapies expected to launch in the market are Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others. The increasing R&D investments for strong Alopecia Areata pipeline candidates by prominent players such as Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, and others will contribute positively to the Alopecia Areata treatment landscape in the forthcoming years. Alopecia Areata Overview Alopecia areata is an autoimmune disorder that results in sudden hair loss. It occurs when the immune system mistakenly targets hair follicles, causing them to shrink and enter a dormant phase. This leads to hair thinning or complete hair loss in round or oval patches on the scalp or other parts of the body. The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic and environmental factors. It can affect individuals of any age, gender, or ethnic background. While alopecia areata is generally not a life-threatening condition, it can have a significant psychological and emotional impact on those affected. The unpredictable nature of hair loss and its potential for recurrence can cause distress and self-esteem issues. There is currently no known cure for alopecia areata, but various treatment options aim to stimulate hair regrowth and manage the condition. These may include topical corticosteroids, topical immunotherapy, oral medications, and injectable medications. Hairpieces, wigs, or cosmetic camouflage techniques can also be utilized to cover areas of hair loss. Learn more about Alopecia Areata treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Alopecia Areata Treatment Market Alopecia Areata Market The Alopecia Areata market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alopecia Areata market trends by analyzing the impact of current Alopecia Areata therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia Areata market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Alopecia Areata market in 7MM is expected to witness a major change in the study period 2020-2034. Alopecia Areata Epidemiology The Alopecia Areata epidemiology section provides insights into the historical and current Alopecia Areata patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alopecia Areata market report also provides the diagnosed patient pool, trends, and assumptions. Alopecia Areata Drugs Uptake This section focuses on the uptake rate of the potential Alopecia Areata drugs recently launched in the Alopecia Areata market or expected to be launched in 2020-2034. The analysis covers the Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug. Alopecia Areata Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alopecia Areata market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Alopecia Areata Pipeline Development Activities The Alopecia Areata report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key Alopecia Areata companies involved in developing targeted therapeutics. Alopecia Areata Therapeutics Assessment Major key companies are working proactively in the Alopecia Areata Therapeutics market to develop novel therapies which will drive the Alopecia Areata treatment markets in the upcoming years are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others. Scope of the Alopecia Areata Market Report: Coverage: 7MM Study Period: 2020-2034 Alopecia Areata Companies: Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare, Arena Pharmaceuticals, LEO Pharma, Aclaris Therapeutics, Bristol-Myers Squibb, Novartis, and many others. Alopecia Areata Drugs: Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others. Alopecia Areata Report Key Insights 1. Alopecia Areata Patient Population 2. Alopecia Areata Market Size and Trends 3. Key Cross Competition in the Alopecia Areata Market 4. Alopecia Areata Market Dynamics (Key Drivers and Barriers) 5. Alopecia Areata Market Opportunities 6. Alopecia Areata Therapeutic Approaches 7. Alopecia Areata Pipeline Analysis 8. Alopecia Areata Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Alopecia Areata Market Table of Contents 1. Key Insights 2. Executive Summary 3. Alopecia Areata Competitive Intelligence Analysis 4. Alopecia Areata Market Overview at a Glance 5. Alopecia Areata Disease Background and Overview 6. Alopecia Areata Patient Journey 7. Alopecia Areata Epidemiology and Patient Population 8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices 9. Alopecia Areata Unmet Needs 10. Key Endpoints of Alopecia Areata Treatment 11. Alopecia Areata Marketed Products 12. Alopecia Areata Emerging Therapies 13. Alopecia Areata Seven Major Market Analysis 14. Attribute Analysis 15. Alopecia Areata Market Outlook (7 major markets) 16. Alopecia Areata Access and Reimbursement Overview 17. KOL Views on the Alopecia Areata Market 18. Alopecia Areata Market Drivers 19. Alopecia Areata Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Yahoo
16-06-2025
- Business
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-06-2025
- Business
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis' common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates. Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis' unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit or follow Arcutis on LinkedIn, Facebook, Instagram and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the 'Risk Factors' section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Contacts:Amanda Sheldon, Head of Corporate Communicationsmedia@ Latha Vairavan, Chief Financial Officerir@ in to access your portfolio
